SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
Abstract In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/55c1ee5b35944f61996ba98978bdc16d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:55c1ee5b35944f61996ba98978bdc16d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:55c1ee5b35944f61996ba98978bdc16d2021-12-02T10:49:16ZSARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness10.1038/s41598-021-81629-22045-2322https://doaj.org/article/55c1ee5b35944f61996ba98978bdc16d2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81629-2https://doaj.org/toc/2045-2322Abstract In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness.Chandima JeewandaraDeshni JayathilakaLaksiri GomesAnanda WijewickramaEranga NarangodaDamayanthi IdampitiyaDinuka GurugeRuwan WijayamuniSuranga ManilgamaGraham S. OggChee Wah TanLin-Fa WangGathsaurie Neelika MalavigeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Chandima Jeewandara Deshni Jayathilaka Laksiri Gomes Ananda Wijewickrama Eranga Narangoda Damayanthi Idampitiya Dinuka Guruge Ruwan Wijayamuni Suranga Manilgama Graham S. Ogg Chee Wah Tan Lin-Fa Wang Gathsaurie Neelika Malavige SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |
| description |
Abstract In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness. |
| format |
article |
| author |
Chandima Jeewandara Deshni Jayathilaka Laksiri Gomes Ananda Wijewickrama Eranga Narangoda Damayanthi Idampitiya Dinuka Guruge Ruwan Wijayamuni Suranga Manilgama Graham S. Ogg Chee Wah Tan Lin-Fa Wang Gathsaurie Neelika Malavige |
| author_facet |
Chandima Jeewandara Deshni Jayathilaka Laksiri Gomes Ananda Wijewickrama Eranga Narangoda Damayanthi Idampitiya Dinuka Guruge Ruwan Wijayamuni Suranga Manilgama Graham S. Ogg Chee Wah Tan Lin-Fa Wang Gathsaurie Neelika Malavige |
| author_sort |
Chandima Jeewandara |
| title |
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |
| title_short |
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |
| title_full |
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |
| title_fullStr |
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |
| title_full_unstemmed |
SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |
| title_sort |
sars-cov-2 neutralizing antibodies in patients with varying severity of acute covid-19 illness |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/55c1ee5b35944f61996ba98978bdc16d |
| work_keys_str_mv |
AT chandimajeewandara sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT deshnijayathilaka sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT laksirigomes sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT anandawijewickrama sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT eranganarangoda sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT damayanthiidampitiya sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT dinukaguruge sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT ruwanwijayamuni sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT surangamanilgama sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT grahamsogg sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT cheewahtan sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT linfawang sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness AT gathsaurieneelikamalavige sarscov2neutralizingantibodiesinpatientswithvaryingseverityofacutecovid19illness |
| _version_ |
1718396589727285248 |